Followers | 3 |
Posts | 313 |
Boards Moderated | 0 |
Alias Born | 06/18/2013 |
Wednesday, October 29, 2014 5:08:08 PM
Revenue of 33,736,682.64 USD in 3rd Qtr. for Kunming Pharmaceutical Group Co., Ltd.
I don't mean to confuse things, so I apologize if I have the wrong company. However, I think I just found the current financials for the 3rd Qtr for Kunming Pharmaceutical Group.
Kunming Pharmaceutical Group Co., Ltd.
http://finance.sina.com.cn/stock/t/20141022/010020602347.shtml
An Important Notice
1.1 Board of Directors, supervisors and directors, supervisors and senior management personnel shall guarantee the authenticity of this quarterly report, accurate, complete, and there is no false records, misleading statements or material omissions, and assume joint and several liability.
1.2 All directors attended the Board of Directors reviewed the quarterly report.
1.3 The person in charge of HE Qin, director of accounting and Wang Shao-wide accounting department (accounting officer) Zhu Youqiang guarantee financial statements quarterly report is true, accurate and complete.
1.4 The third quarterly report is unaudited.
Second, changes in key financial data and company shareholders
2.1 Key Financial Data
Unit: Currency: RMB
This reporting period
End of last year
Over the end of the reporting period the previous year change (%)
Total assets
2,922,875,251.39
2,885,839,475.35
1.28
Net assets attributable to shareholders of listed companies
1,841,760,489.85
1,757,991,412.79
4.77
Year to the end of the period
(January to September)
The beginning of the reporting period to the previous year
(January to September)
Than last year (%)
Net cash flow from operating activities
206,151,436.86
128,917,517.89
59.91
Year to the end of the period
(January to September)
The beginning of the reporting period to the previous year
(January to September)
Decrease over the previous year
(%)
Operating income
2,904,622,676.29
2,598,663,326.47
11.77
Net profit attributable to shareholders of listed companies
203,165,839.01
163,624,521.24
24.17
Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses
174,551,637.39
159,074,110.41
9.73
Weighted average return on net assets (%)
10.93
14.37
3.44 percentage point reduction
Basic earnings per share (RMB / share)
0.5956
0.4797
24.16
Diluted earnings per share (RMB / share)
0.5956
0.4797
24.16
The total number of shareholders and top ten shareholders and the top ten tradable shareholders 2.2 cutoff of the reporting period (or tradable shareholders) holding Fact Sheet
Unit: Share
Total number of shareholders (households)
15036
The top ten shareholders
Name of shareholder
Changes in the reporting period
Closing number of shares
Percentage (%)
Number of shares held by moratorium
Pledged or frozen
Nature of shareholders
(Full name)
Shares state
Quantity
Hua Fang Pharmaceutical Co., Ltd.
0
64,250,225
18.83
0
Freeze
6,000,000
Domestic non-state-owned legal person
Yunnan Hongta Group Co., Ltd.
0
29,991,365
8.79
0
Unknown
Domestic non-state-owned legal person
China Construction Bank(4.07, 0.03, 0.74%) Co., Ltd. - Manulife TEDA efficiency optimization hybrid securities investment fund
-1,732,740
10,956,337
3.21
0
Unknown
Other
China Industrial and Commercial Bank of China(3.54, 0.02, 0.57%) - Huitianfu Growth Securities Investment Fund
-4,004,690
9,500,000
2.78
0
Unknown
Other
Yunnan Industrial Investment Holding Group Co., Ltd.
0
5,287,108
1.55
0
Unknown
State-owned corporation
China Everbright Bank(2.69, 0.04, 1.51%) Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund
-950,007
5,210,084
1.53
0
Unknown
Other
Bank of China(2.69, 0.05, 1.89%) - Franklin Templeton Sealand potential combination Securities Investment Fund
-1,435,599
5,000,000
1.47
0
Unknown
Other
Fujian Ping
4,954,903
1.45
0
Unknown
Domestic natural person
Bank of China - Harvest Theme Selected Mixed Securities Investment Fund
4,799,863
1.41
0
Unknown
Other
China Ping An(42.05, 1.34, 3.29%) Life Insurance Company Limited - Traditional - General Insurance
-5,900,400
4,700,316
1.38
0
Unknown
Other
Top ten tradable shareholders
Name of shareholder
Hold the number of tradable shares
The type and quantity of shares
Species
Quantity
Hua Fang Pharmaceutical Co., Ltd.
64,250,225
RMB ordinary shares
64,250,225
Yunnan Hongta Group Co., Ltd.
29,991,365
RMB ordinary shares
29,991,365
China Construction Bank Corporation [microblogging] - Manulife TEDA efficiency optimization hybrid securities investment fund
10,956,337
RMB ordinary shares
10,956,337
ICBC China - Huitianfu Growth Securities Investment Fund
9,500,000
RMB ordinary shares
9,500,000
Yunnan Industrial Investment Holding Group Co., Ltd.
5,287,108
RMB ordinary shares
5,287,108
China Everbright Bank Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund
5,210,084
RMB ordinary shares
5,210,084
Bank of China - Franklin Templeton Sealand potential combination Securities Investment Fund
5,000,000
RMB ordinary shares
5,000,000
Fujian Ping
4,954,903
RMB ordinary shares
4,954,903
Bank of China - Harvest Theme Selected Mixed Securities Investment Fund
4,799,863
RMB ordinary shares
4,799,863
China Ping [microblogging] Life Insurance Company Limited - Traditional - General Insurance
4,700,316
RMB ordinary shares
4,700,316
The shareholders' association or the concerted action
Restoration of voting rights and number of shares of preferred shareholders description
Third, the important issues
3.1 The main financial statements and financial indicators and the reasons for significant changes
v Applicable ? NA
Unit: Currency: RMB
Account Name
Issue / Closing
The previous period / early
Changes in the ratio (%)
Reasons for change
Accounts receivable
472,633,488.86
362,618,240.41
30.34
Increase customer arrears issue
Other receivables
109,757,815.75
58,032,164.72
89.13
Margin increased land issue
Other current assets
396,114,411.41
552,503,364.83
-28.31
Reduce the current investment products
Fixed assets
398,823,870.41
301,889,674.38
32.11
Construction in progress carried forward
Construction in progress
90,097,591.07
192,450,644.14
-53.18
Construction in progress carried forward
Short-term borrowings
124,500,000.00
30,000,000.00
315.00
Increase in current loans
Long-term borrowings
24,500,000.00
0
Not applicable
This issue loans increased, the period without
Other payables
264,793,661.03
170,055,987.79
55.71
With revenue growth and growth
Business tax and surcharges
19,406,021.39
14,792,894.51
31.18
With revenue growth and growth
Financial expenses
8,820,278.17
20,203,985.02
-56.34
On repayment of short-term financial interest, no issue
Impairment losses on assets
2,478,232.36
6,020,247.04
-58.84
On equity of provision for impairment, no issue
Net cash flow from operating activities
206,151,436.86 or 33,736,682.64 USD
128,917,517.89
59.91
Increase the current cash payment
Net cash flow from investing activities
-147,867,599.21
-632,378,083.72
Not applicable
The current project expenditure reduced?
Net cash flow from financing activities
85,920,732.62
509,022,840.76
-83.12
The public issuance of shares, issue no?
3.2 Company and shareholder holding more than 5% of the fulfillment of commitments
v Applicable ? NA
Commitment background
Commitment type
Commitment party
Commitment Content
Commitment of time and deadlines
Are there performance period
Implementation of the commitments
Commitments associated with refinancing
Resolve intra-industry competition
Actual control
Actual control of the issuer for the current situation with the competition in terms of the presence of artemisinin, on December 24, 2012 commitment: "The current anti-malarial Artemisia annua industry charitable industry, mainly large international pharmaceutical company Novartis, Sanofi and other monopolies, the above related parties artemisinin business achieve lower annual profit, and therefore require long-term cultivation of listed companies will contribute to make the light of historical issues, in the next five years, according to artemisinin overall market conditions, companies annua prime business development, the degree of recognition of the capital market, through asset acquisitions, restructuring and other means, to develop specific operation of the program, step by step, so as to solve the Kunming system
Artemisinin drugs in terms of competition with the industry scenario. "To solve the issuer and the actual controller of other companies in the same industry in terms of artemisinin competition, the actual controller Wang Licheng on March 22, 2013 to be adopted in the following manner in order to avoid competition: (1) will continue to remain in Kunming Pharmaceuticals(26.81, 0.14, 0.52%) existing good corporate governance structure, fully maintain independence in Kunming Pharmaceutical assets, personnel, business, institutional, financial aspects, to ensure that listed companies Kunming Pharmaceutical norms by independent operators to ensure the Kunming Pharmaceutical an independent and complete business system and independent operators the ability to directly market-oriented; (2) the actual controller will be invested at fair treatment of all enterprises, and not used as the actual control status or use of information obtained in this position, make no conducive to the issuer and the decision in favor of other companies, if the issues related to the actual controller directly intervene in specific production and business activities of enterprises, which results in a loss of the issuer, the actual controller will take the responsibility; and (3) to take positive measures to eliminate the issuer and with the competition or potential competition with the status of artemisinin-based enterprises under the control of actual control between the specific measures including, but not limited to:. a In five years, that is, before 31 December 2017, and gradually to mergers and acquisitions, restructuring and business restructuring, etc., to complete the issuer Kunming Pharmaceutical application documents issuance of A shares prospectus assets and business 1-1-131 and the actual control under the control of artemisinin-based enterprise integration between .b. assist issuers the introduction of new external strategic investors to optimize corporate governance structure c. progressively to mergers and acquisitions, restructuring and business restructuring, etc., to complete the integration of the assets and business of the issuer under artemisinin-based enterprises and the actual control between control by the above measures over the next five years, it will completely solve the issuer and the actual control under the control of artemisinin-based companies with the competition.
December 31, 2017
Are
As of this announcement, the commitment to strictly fulfill the commitments (1), (2), does not appear contrary to the case of the above commitments.
Commitments associated with refinancing
Solve the related party transactions
Controlling shareholder and actual controller
The controlling shareholder of the Company, of commitments: As the controlling shareholder of Kunming Pharmaceutical, the actual controller, will minimize and regulate related party transactions between its subsidiaries and Kunming Pharmaceutical. For unavoidable or have reasonable grounds related transactions occurred, including but not limited to, commodity trading, providing services to each other, or as a proxy, the company will strictly follow all equivalent, paid the principles of fair trade, fair trade in a market does not require the Kunming Pharmaceutical and its subsidiaries provide superior to any third party or giving third parties the conditions and in accordance with "related trading system" and other normative documents related to the articles of association and the Kunming Pharmaceutical fulfill the legal approval process and enter into related agreements / contract, timely information disclosure norms related transactions, to ensure that no damage to the legitimate interests of related party transactions by Kunming Pharmaceutical and other shareholders, to raise funds to ensure that this issue does not generate new investment projects related party transactions.
No
As of this announcement, the commitment to strictly fulfill this commitment, the commitment does not appear contrary to the above case.
Kunming Pharmaceutical Group Co., Ltd.
Chairman: HE Qin
October 21, 2014
Enter [Reuters shares it] discussion
I don't mean to confuse things, so I apologize if I have the wrong company. However, I think I just found the current financials for the 3rd Qtr for Kunming Pharmaceutical Group.
Kunming Pharmaceutical Group Co., Ltd.
http://finance.sina.com.cn/stock/t/20141022/010020602347.shtml
An Important Notice
1.1 Board of Directors, supervisors and directors, supervisors and senior management personnel shall guarantee the authenticity of this quarterly report, accurate, complete, and there is no false records, misleading statements or material omissions, and assume joint and several liability.
1.2 All directors attended the Board of Directors reviewed the quarterly report.
1.3 The person in charge of HE Qin, director of accounting and Wang Shao-wide accounting department (accounting officer) Zhu Youqiang guarantee financial statements quarterly report is true, accurate and complete.
1.4 The third quarterly report is unaudited.
Second, changes in key financial data and company shareholders
2.1 Key Financial Data
Unit: Currency: RMB
This reporting period
End of last year
Over the end of the reporting period the previous year change (%)
Total assets
2,922,875,251.39
2,885,839,475.35
1.28
Net assets attributable to shareholders of listed companies
1,841,760,489.85
1,757,991,412.79
4.77
Year to the end of the period
(January to September)
The beginning of the reporting period to the previous year
(January to September)
Than last year (%)
Net cash flow from operating activities
206,151,436.86
128,917,517.89
59.91
Year to the end of the period
(January to September)
The beginning of the reporting period to the previous year
(January to September)
Decrease over the previous year
(%)
Operating income
2,904,622,676.29
2,598,663,326.47
11.77
Net profit attributable to shareholders of listed companies
203,165,839.01
163,624,521.24
24.17
Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses
174,551,637.39
159,074,110.41
9.73
Weighted average return on net assets (%)
10.93
14.37
3.44 percentage point reduction
Basic earnings per share (RMB / share)
0.5956
0.4797
24.16
Diluted earnings per share (RMB / share)
0.5956
0.4797
24.16
The total number of shareholders and top ten shareholders and the top ten tradable shareholders 2.2 cutoff of the reporting period (or tradable shareholders) holding Fact Sheet
Unit: Share
Total number of shareholders (households)
15036
The top ten shareholders
Name of shareholder
Changes in the reporting period
Closing number of shares
Percentage (%)
Number of shares held by moratorium
Pledged or frozen
Nature of shareholders
(Full name)
Shares state
Quantity
Hua Fang Pharmaceutical Co., Ltd.
0
64,250,225
18.83
0
Freeze
6,000,000
Domestic non-state-owned legal person
Yunnan Hongta Group Co., Ltd.
0
29,991,365
8.79
0
Unknown
Domestic non-state-owned legal person
China Construction Bank(4.07, 0.03, 0.74%) Co., Ltd. - Manulife TEDA efficiency optimization hybrid securities investment fund
-1,732,740
10,956,337
3.21
0
Unknown
Other
China Industrial and Commercial Bank of China(3.54, 0.02, 0.57%) - Huitianfu Growth Securities Investment Fund
-4,004,690
9,500,000
2.78
0
Unknown
Other
Yunnan Industrial Investment Holding Group Co., Ltd.
0
5,287,108
1.55
0
Unknown
State-owned corporation
China Everbright Bank(2.69, 0.04, 1.51%) Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund
-950,007
5,210,084
1.53
0
Unknown
Other
Bank of China(2.69, 0.05, 1.89%) - Franklin Templeton Sealand potential combination Securities Investment Fund
-1,435,599
5,000,000
1.47
0
Unknown
Other
Fujian Ping
4,954,903
1.45
0
Unknown
Domestic natural person
Bank of China - Harvest Theme Selected Mixed Securities Investment Fund
4,799,863
1.41
0
Unknown
Other
China Ping An(42.05, 1.34, 3.29%) Life Insurance Company Limited - Traditional - General Insurance
-5,900,400
4,700,316
1.38
0
Unknown
Other
Top ten tradable shareholders
Name of shareholder
Hold the number of tradable shares
The type and quantity of shares
Species
Quantity
Hua Fang Pharmaceutical Co., Ltd.
64,250,225
RMB ordinary shares
64,250,225
Yunnan Hongta Group Co., Ltd.
29,991,365
RMB ordinary shares
29,991,365
China Construction Bank Corporation [microblogging] - Manulife TEDA efficiency optimization hybrid securities investment fund
10,956,337
RMB ordinary shares
10,956,337
ICBC China - Huitianfu Growth Securities Investment Fund
9,500,000
RMB ordinary shares
9,500,000
Yunnan Industrial Investment Holding Group Co., Ltd.
5,287,108
RMB ordinary shares
5,287,108
China Everbright Bank Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund
5,210,084
RMB ordinary shares
5,210,084
Bank of China - Franklin Templeton Sealand potential combination Securities Investment Fund
5,000,000
RMB ordinary shares
5,000,000
Fujian Ping
4,954,903
RMB ordinary shares
4,954,903
Bank of China - Harvest Theme Selected Mixed Securities Investment Fund
4,799,863
RMB ordinary shares
4,799,863
China Ping [microblogging] Life Insurance Company Limited - Traditional - General Insurance
4,700,316
RMB ordinary shares
4,700,316
The shareholders' association or the concerted action
Restoration of voting rights and number of shares of preferred shareholders description
Third, the important issues
3.1 The main financial statements and financial indicators and the reasons for significant changes
v Applicable ? NA
Unit: Currency: RMB
Account Name
Issue / Closing
The previous period / early
Changes in the ratio (%)
Reasons for change
Accounts receivable
472,633,488.86
362,618,240.41
30.34
Increase customer arrears issue
Other receivables
109,757,815.75
58,032,164.72
89.13
Margin increased land issue
Other current assets
396,114,411.41
552,503,364.83
-28.31
Reduce the current investment products
Fixed assets
398,823,870.41
301,889,674.38
32.11
Construction in progress carried forward
Construction in progress
90,097,591.07
192,450,644.14
-53.18
Construction in progress carried forward
Short-term borrowings
124,500,000.00
30,000,000.00
315.00
Increase in current loans
Long-term borrowings
24,500,000.00
0
Not applicable
This issue loans increased, the period without
Other payables
264,793,661.03
170,055,987.79
55.71
With revenue growth and growth
Business tax and surcharges
19,406,021.39
14,792,894.51
31.18
With revenue growth and growth
Financial expenses
8,820,278.17
20,203,985.02
-56.34
On repayment of short-term financial interest, no issue
Impairment losses on assets
2,478,232.36
6,020,247.04
-58.84
On equity of provision for impairment, no issue
Net cash flow from operating activities
206,151,436.86 or 33,736,682.64 USD
128,917,517.89
59.91
Increase the current cash payment
Net cash flow from investing activities
-147,867,599.21
-632,378,083.72
Not applicable
The current project expenditure reduced?
Net cash flow from financing activities
85,920,732.62
509,022,840.76
-83.12
The public issuance of shares, issue no?
3.2 Company and shareholder holding more than 5% of the fulfillment of commitments
v Applicable ? NA
Commitment background
Commitment type
Commitment party
Commitment Content
Commitment of time and deadlines
Are there performance period
Implementation of the commitments
Commitments associated with refinancing
Resolve intra-industry competition
Actual control
Actual control of the issuer for the current situation with the competition in terms of the presence of artemisinin, on December 24, 2012 commitment: "The current anti-malarial Artemisia annua industry charitable industry, mainly large international pharmaceutical company Novartis, Sanofi and other monopolies, the above related parties artemisinin business achieve lower annual profit, and therefore require long-term cultivation of listed companies will contribute to make the light of historical issues, in the next five years, according to artemisinin overall market conditions, companies annua prime business development, the degree of recognition of the capital market, through asset acquisitions, restructuring and other means, to develop specific operation of the program, step by step, so as to solve the Kunming system
Artemisinin drugs in terms of competition with the industry scenario. "To solve the issuer and the actual controller of other companies in the same industry in terms of artemisinin competition, the actual controller Wang Licheng on March 22, 2013 to be adopted in the following manner in order to avoid competition: (1) will continue to remain in Kunming Pharmaceuticals(26.81, 0.14, 0.52%) existing good corporate governance structure, fully maintain independence in Kunming Pharmaceutical assets, personnel, business, institutional, financial aspects, to ensure that listed companies Kunming Pharmaceutical norms by independent operators to ensure the Kunming Pharmaceutical an independent and complete business system and independent operators the ability to directly market-oriented; (2) the actual controller will be invested at fair treatment of all enterprises, and not used as the actual control status or use of information obtained in this position, make no conducive to the issuer and the decision in favor of other companies, if the issues related to the actual controller directly intervene in specific production and business activities of enterprises, which results in a loss of the issuer, the actual controller will take the responsibility; and (3) to take positive measures to eliminate the issuer and with the competition or potential competition with the status of artemisinin-based enterprises under the control of actual control between the specific measures including, but not limited to:. a In five years, that is, before 31 December 2017, and gradually to mergers and acquisitions, restructuring and business restructuring, etc., to complete the issuer Kunming Pharmaceutical application documents issuance of A shares prospectus assets and business 1-1-131 and the actual control under the control of artemisinin-based enterprise integration between .b. assist issuers the introduction of new external strategic investors to optimize corporate governance structure c. progressively to mergers and acquisitions, restructuring and business restructuring, etc., to complete the integration of the assets and business of the issuer under artemisinin-based enterprises and the actual control between control by the above measures over the next five years, it will completely solve the issuer and the actual control under the control of artemisinin-based companies with the competition.
December 31, 2017
Are
As of this announcement, the commitment to strictly fulfill the commitments (1), (2), does not appear contrary to the case of the above commitments.
Commitments associated with refinancing
Solve the related party transactions
Controlling shareholder and actual controller
The controlling shareholder of the Company, of commitments: As the controlling shareholder of Kunming Pharmaceutical, the actual controller, will minimize and regulate related party transactions between its subsidiaries and Kunming Pharmaceutical. For unavoidable or have reasonable grounds related transactions occurred, including but not limited to, commodity trading, providing services to each other, or as a proxy, the company will strictly follow all equivalent, paid the principles of fair trade, fair trade in a market does not require the Kunming Pharmaceutical and its subsidiaries provide superior to any third party or giving third parties the conditions and in accordance with "related trading system" and other normative documents related to the articles of association and the Kunming Pharmaceutical fulfill the legal approval process and enter into related agreements / contract, timely information disclosure norms related transactions, to ensure that no damage to the legitimate interests of related party transactions by Kunming Pharmaceutical and other shareholders, to raise funds to ensure that this issue does not generate new investment projects related party transactions.
No
As of this announcement, the commitment to strictly fulfill this commitment, the commitment does not appear contrary to the above case.
Kunming Pharmaceutical Group Co., Ltd.
Chairman: HE Qin
October 21, 2014
Enter [Reuters shares it] discussion
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.